IVVD SHAREHOLDER ALERT: Jakubowitz Law Reminds Invivyd Shareholders of a Lead Plaintiff Deadline of April 3, 2023

NEW YORK, March 31, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD).

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/invivyd-inc-f-k-a-adagio-therapeutics-inc-loss-submission-form/?id=37893&from=4

This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until April 3, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887

SOURCE Jakubowitz Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED